• Career for Scientific Officer in Regional Drugs Testing Laboratory, CDSCO
    26 August 2026

    Career for Scientific Officer in Regional Drugs Testing Laboratory, CDSCO

    Masters degree in Chemistry or Biochemistry or Pharmacy or Pharmaceutical Chemistry or Pharmacology or Bacteriology or Medicine or Microbiology or Biotechnology of a recognized university or institute. Regional Drugs Testing Laboratory, Guwahati, CDSCO, DGHS, Ministry of Health & Family Welfare.
  • 24 August 2026
    CDSCO Flags 239 Drug Samples as Not of Standard Quality in July 2026 Alert

    The Central Drugs Standard Control Organization (CDSCO) has released its July 2026 Not of Standard Quality (NSQ) drug alert, listing a large number of medicine samples that failed to meet specified quality standards during testing by state and CDSCO laboratories.

  • 15 August 2026
    CDSCO SEC Recommends Phase IV Clinical Trial of Dostarlimab for Endometrial Cancer

    The Subject Expert Committee (Oncology) of the Central Drugs Standard Control Organisation (CDSCO) has recommended granting permission to conduct a Phase IV clinical trial of dostarlimab in adult patients in India with primary advanced or recurrent endometrial cancer. The recommendation was made during the SEC (Oncology) meeting held on August 5, 2026, at CDSCO Headquarters, New Delhi.

  • 15 August 2026
    CDSCO Directs IND Division to Process Applications for Unapproved New Drugs Under Review by Foreign Regulators

    The Central Drugs Standard Control Organisation (CDSCO) has clarified that applications seeking permission to import and market new drugs that are not approved anywhere in the world, where Phase III Global Clinical Trials (GCTs) are either ongoing or have been completed with the participation of Indian subjects, will be examined and processed by the Investigational New Drug (IND) Division.

  • 17 July 2026
    Career for Pharmacy or Chemistry or Biochemistry Professionals to Join RDTL
    Masters degree in Chemistry or Biochemistry or Pharmacy or Pharmaceutical Chemistry or Pharmacology or Bacteriology or Medicine or Microbiology or Biotechnology from a recognized university or Institute.
  • 17 July 2026
    CDSCO Panel Rejects Dexlansoprazole–Domperidone FDC Proposal

    The Subject Expert Committee (SEC) on Gastroenterology and Hepatology has declined to recommend approval of a Fixed Dose Combination (FDC) containing Dexlansoprazole (enteric coated pellets) 60 mg and Domperidone (sustained release pellets) 30 mg capsules proposed by MSN Laboratories Private Limited.

    The decision was taken during the 08th/26 SEC meeting held on 9 July 2026 at the CDSCO Headquarters, New Delhi, after the company presented its proposal before the committee.

  • 9 July 2026
    CDSCO Rejects Trial Waiver for Roche’s Glofitamab, Seeks Phase III Study Before India Approval

    The Subject Expert Committee (SEC) on Oncology has declined Roche Products (India) Private Limited's request for a waiver of local Phase III and Phase IV clinical trials for Glofitamab and has instead recommended that the company conduct Phase III clinical trials in India before the drug can be considered for marketing approval.

  • 30 June 2026
    Opportunity for Pharmacy or Chemistry or Biochemistry Professionals to Join RDTL
    Masters degree in Chemistry or Biochemistry or Pharmacy or Pharmaceutical Chemistry or Pharmacology or Bacteriology or Medicine or Microbiology or Biotechnology of a recognised university or institute.
  • 30 June 2026
    CDSCO Restricts Supply of IVF Media and Reagents to Registered ART Centres Only
    The Central Drugs Standard Control Organization (CDSCO) has issued a public interest circular directing all stakeholders to ensure that In-Vitro Fertilization (IVF) media, reagents, and related consumables are supplied only to centres registered under the Assisted Reproductive Technology (Regulation) Act, 2021 and the Surrogacy (Regulation) Act, 2021.
  • 30 June 2026
    CDSCO Clarifies Approval Pathway for Formulation Intermediates, Modified Release Granules and Pellets

    The Central Drugs Standard Control Organization (CDSCO) has issued a major clarification regarding the regulatory approval process for formulation intermediates, including directly compressible granules, taste-masked granules, modified-release granules, pellets, and similar intermediates used in pharmaceutical manufacturing. The clarification aims to establish uniform licensing practices across India and eliminate confusion among manufacturers.

Subscribe to CDSCO